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Combined effects of the bisphosphonate, zoledronic acid and the
aromatase inhibitor letrozole on breast cancer cells in vitro:
evidence of synergistic interaction
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BACKGROUND: Aromatase inhibitors are widely used in the treatment of oestrogen receptor-positive post-menopausal breast cancer.
These patients may also be receiving the bisphosphonate, zoledronic acid (ZA) to prevent bone loss or reduce skeletal morbidity in
the setting of advanced disease. The potential biological interaction of these two drugs in breast cancer has not been assessed.
METHODS: Aromatase-expressing breast cancer cells were treated with letrozole and ZA either simultaneously or in sequence, and the
resulting apoptosis was assessed by staining with Hoechst 33342 and propidium iodide and examined using a fluorescent inverted
Leica DMIRB microscope and a UV filter.
RESULTS: We found that letrozole and ZA induce levels of apoptosis in breast cancer cells in vitro that are significantly greater
compared with treatment with each drug alone. However, this potentially, synergistic relationship is drug-sequence dependent,
occurring only when cells are treated with letrozole, followed by ZA. The converse sequence, or administering drugs simultaneously,
induces levels of apoptosis no greater than each drug alone.
CONCLUSION: Owing to the enhanced anti-tumour efficacy of sequential drug administration, our findings may indicate that, for
post-menopausal women who require treatment with letrozole, ZA should also be considered.
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Letrozole is a non-steroidal third-generation aromatase inhibitor
(AI) that binds to aromatase, which controls the last step in
oestrogen synthesis. The AIs induce a profound reduction in
oestradiol, oestrone and oestrone sulphate levels and, as a result,
inhibit the growth of oestrogen-dependent breast cancer. In post-
menopausal breast cancer, AIs are increasingly used in both
metastatic (Mouridsen et al, 2001) and adjuvant settings (BIG1-98
Collaborators 2009; Goss et al, 2005).
Breast cancer patients may also require bisphosphonate,
zoledronic acid (ZA) for various reasons. For example, letrozole
(as with other AIs) causes bone loss and increases the risk of
osteoporosis (Lester and Coleman, 2005). In addition, there is
growing evidence for an adjuvant function for bisposphonates in
early breast cancer (Gnant et al, 2009). Finally, patients may also
be receiving ZA for metastatic bone disease, to reduce skeletal
morbidity and pain (Rosen et al, 2001). As a result, increasing
numbers of patients are receiving both ZA and letrozole in
combination, either in early or advanced breast cancer. Table 1
lists current trials involving both ZA and letrozole in breast cancer
that are either actively recruiting patients or closed to recruitment,
but with results awaited.
The ZA is a potent nitrogen-containing bisphosphonate that
inhibits osteoclastic bone resorption (Green et al, 1994). All
nitrogen-containing bisphosphonates inhibit farnesyl pyrophos-
phate synthase in the mevalonate pathway (Dunford et al,
2001), leading to inhibition of farnesyl pyrophosphate and
geranylgeranyl pyrophosphate. These isoprenoids are required
for the post-translation lipid modification (i.e. farnesylation and
geranylgeranylation) of signalling GTPases, such as Ras, Rho and
Rac (Rogers et al, 2000). As these control a variety of important
osteoclast cell functions, their loss ultimately leads to osteoclast
apoptosis through caspase-3 enzyme activation (Benford et al,
2001).
In vitro, ZA also affects cancer cells directly through a wide
variety of mechanisms. These include induction of apoptosis,
inhibition of cancer cell growth, reduction of cancer cell adhesion,
invasion and anti-angiogenic effects. Many of these anti-tumour
effects are specifically related to inhibition of the mevalonate
pathway, with potential for even greater anti-tumour activity when
combined with other drugs (reviewed by Winter et al, 2008). To
date, the interactions between ZA and letrozole on breast cancer
cells in vitro have not been studied.
We have investigated whether ZA and letrozole, using cell
culture conditions that mimic the post-menopausal state, have
the potential for synergistic induction of apoptosis in breast cancer
cells in vitro, and present novel insights into the interaction
of ZA and the AI, letrozole.
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MATERIALS AND METHODS
Tissue culture
To study the effect of letrozole in vitro, the human breast cancer
cell line, MCF7-Ca, was used (provided by Dr S Chen New York,
USA). This is an oestrogen receptor- and aromatase gene-expres-
sing breast cancer cell line. For experiments using ZA alone, cells
were routinely maintained in RPMI 1640 media, supplemented
with 10% foetal calf serum (FCS), glutamine (2mM) (all purchased
from Gibco, Invitrogen Corporation, Paisley, UK), penicillin
(100Uml–1), streptomycin (100 mgml–1) (both purchased from
GlaxoSmithKline, Uxbridge, Middlesex, UK) and fungizone
(Amphoteracin B) (5 mgml–1) (Invitrogen Life Technologies Ltd,
Paisley, Renfrewshire, UK).
To mimic post-menopausal oestrogen levels, it was necessary to
deplete the medium of available oestrogen and add the aromatase
substrate, androstenedione (AD). Under these conditions the only
oestrogen available to cells would be through conversion of AD to
oestrogen by the aromatase enzyme. Therefore, cells were grown
and treated in phenol-red-free, glutamine-free RPMI 1640 media
(purchased from Gibco, Invitrogen Corporation), supplemented
with dextran-coated charcoal-stripped (from Sigma-Aldrich, Poole,
Dorset, UK) FCS. Phosphate-buffered solution (PBS) Dulbecco
and trypsin-EDTA (0.05% trypsin, 0.53mM EDTA.4Na in
Hanks-buffered saline solution) were supplied by Gibco (Invitrogen
Corporation). All plastics were purchased from Costar Ltd
(Bucks, UK).
Drugs and chemicals
The ZA ([1-hydroxy-2-(1H-imidazol-1-yl)ethylidene] bisphos-
phonic acid) was supplied as a disodium salt by Novartis (Basel,
Switzerland). A stock solution (10mM) was prepared in PBS and
stored at 201C. Letrozole was also a gift from Novartis and
supplied as a dry powder that was reconstituted in 100% ethanol
to make a 0.1 M stock solution, and stored at 4–81C. The stock
solution of each drug was diluted in appropriate culture media and
sterile filtered before use.
Geranylgeraniol (GGOH) (all trans-3, 7,11-15-tetramethyl-2,
6,10,14-hexadecatetraen-1-ol) and 4-androsten-3, 17-dione (AD)
were purchased from Sigma-Aldrich. Geranylgeraniol was diluted
in ethanol (1 M stock solution) and stored at 201C. For use in
experiments, it was diluted at least 20 000-fold with culture media.
Androstenedione was supplied as 1mg dry powder, which was
serially diluted in ethanol. A concentration of 25 nM was used for
Table 1 Current trials involving zoledronic acid in conjunction with letrozole, actively recruiting or results awaited, in breast cancer patients
Trial
identification Trial name Phase Sponsor
Number of
patients Status
NCT00050011 Zoledronic acid – letrozole adjuvant synergy trial (ZFAST) – cancer
treatment-related bone loss in post-menopausal women with
oestrogen receptor positive and/or progesterone receptor
positive breast cancer receiving adjuvant hormonal therapy
III Novartis 602 Active, not recruiting,
no results available
NCT00171314 The use of zoledronic acid to prevent cancer-treatment bone
loss in post-menopausal women receiving adjuvant letrozole
for breast cancer
III Novartis 500 Completed, results not
available as yet
NCT00171340 The use of zoledronic acid to prevent cancer-treatment bone
loss in post-menopausal women receiving adjuvant letrozole
for breast cancer
III Novartis 900 Completed, results not
available as yet
NCT00375752 Efficacy and safety of letrozole vs letrozole plus zoledronic acid
as endocrine therapy before surgery in post-menopausal
patients with breast cancer
II/III Novartis 860 Currently recruiting
NCT00332709 Safety/efficacy of letrozole monotherapy or in combination
with zoledronic acid as extended adjuvant treatment of
post-menopausal patients with primary breast cancer
III Novartis 460 Currently recruiting
NCT00247650 Randomized multi-centre study comparing prolonged
primary systemic endocrine therapy with letrozole alone or
in combination with zoledronic acid in early breast cancer
(neoadjuvant study in Canada)
II Novartis 190 Completed, no results
available
NCT00376740 Phase 3 study of the effect of zoledronic acid in the prevention
of osteoporosis in early breast cancer patients receiving the
aromatase inhibitor, letrozole, in the adjuvant setting
III Soroka University
Medical Center
80 Currently recruiting
NCT00114270 Evaluating the effect of letrozole with or without concomitant
zoledronic acid on oestrogen responsive targets in
post-menopausal women
III University of
Virginia
120 Active, not recruiting
NCT00107263 A randomized, controlled, open-label trial of empiric prophylactic
vs delayed use of zoledronic acid for prevention of bone loss
in post-menopausal women with breast cancer initiating therapy
with letrozole after tamoxifen
III North Central
Cancer
Treatment
Group
550 Active, not recruiting
NCT00412022 Phase III randomized study of the effects on bone mineral
density of tamoxifen, letrozole and letrozole + zoledronic
acid as adjuvant treatment of patients with early breast cancer
III National Cancer
Institute, Naples
500 Currently recruiting
NCT00436917 Zoledronic acid for treatment of osteopenia and osteoporosis
in women with primary breast cancer undergoing adjuvant
aromatase inhibitor (letrozole) therapy
Open-label Mayo Clinic 60 Active, not recruiting
NCT00903162 Extended endocrine therapy for pre-menopausal women with
breast cancer
Open-label Dana-Farber
Cancer Institute
50 Currently recruiting
NCT00072020 Does adjuvant zoledronic acid reduce recurrence in patients with
high-risk localised breast cancer? (AZURE)a
III University of
Sheffield
3352 Awaiting results
aPatients may be also receiving chemotherapy or other endocrine agents, not exclusively letrozole, with or without zoledronic acid. Sources: UK clinical trials gateway
(http://www.controlled-trials.com) and Clinicaltrials.gov (http://www.clinicaltrials.gov.ct2/home).
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experiments on the basis of an earlier study by Professor A Brodie
(Thiantanawat et al, 2003).
Treatment of cells
Cells were seeded (at 20 000/0.5ml per well) in 24-well plates and
incubated for 3 days (to confluence) before treatment. On the day
of treatment, cells were washed using 0.5ml of sterile PBS, and an
appropriate culture medium containing the drug(s) of interest was
added to the wells.
Proliferation assay
Cells (MCF7-Ca) were seeded in 24-well plates and treated
with either letrozole (0–100 nM) or ZA (0–25 mM), and at the end
of each specified incubation period, cells were counted using a
Coulter counter (Beckman Coulter, Z series).
Apoptosis assay
At the end of the specified drug treatment period, cells were
stained with 8 mM Hoechst 33342 (Sigma RBI, Poole, Dorset, UK)
and 5 mM propidium iodide (Molecular Probes, Cambridge
Biochemical, Cambridge, UK) for 15min at 371C. Both attached
and detached cells were stained and examined using a fluorescent
inverted Leica DMIRB microscope and a UV filter (355 nm
excitation and 465 nm emission). Propidium iodide was excluded
by viable cells, but stained the nuclei of necrotic cells. Hoechst
33342 entered the nuclei of viable and apoptotic cells, the latter
being recognised by characteristic features of karyorrhexis. The
incidence of viable, apoptotic and necrotic cells was obtained
by counting using a Whipple graticule in five separate random grid
areas in each of three wells for each treatment.
Experiments involving sequential administration of ZA
and letrozole
For these experiments, MCF7-Ca cells were seeded in 24-well
plates, and cells were treated with ZA (10 mM) and letrozole
(100 nM), each for 24 h, alone and in combination, in oestrogen-
free media supplemented with AD (25 nM), as follows (Figure 1
indicates the experiment design):
Group 1, ‘letrozole followed by ZA’: Cells were initially treated
with letrozole on day 1, and after 24 h incubation (day 2), the
cells were washed and then treated with ZA for 24 h until day 3.
At the end of 24 h incubation with ZA, the cells were again washed
and incubated in fresh media (FM) for a further 24 h, with cells
being assessed for apoptosis and necrosis on day 4.
Group 2, ‘ZA followed by letrozole’: Cells were initially treated
with ZA on day 1, and after 24 h incubation (day 2), they were
Drug sequence 1
Letrozole off
zoledronic acid onLetrozole on Apoptotic cells countedZoledronic acid off
Fresh medium
24 h 24 h
Day 1 Day 2 Day 3 Day 4
Day 1 Day 2 Day 3 Day 4
Day 1 Day 2 Day 3 Day 4
Drug sequence 2
Zoledronic acid
on
Zoledronic acid off
letrozole on Letrozole off
Apoptotic cells counted
Fresh medium
24 h 24 h24 h
Drug sequence 3
Letrozole and
zoledronic acid
on
Apoptotic cells counted
Letrozole and
zoledronic acid off
Fresh medium
24 h 48 h
24 h
Figure 1 Experiment design for investigating the effects of sequential treatment of MCF7-Ca cells with letrozole (100 nM) and zoledronic acid (25 mM).
Drug sequence 1: ‘letrozole followed by zoledronic acid’; drug sequence 2: ‘zoledronic acid followed by letrozole’; drug sequence 3: ‘zoledronic acid and
letrozole together’).
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washed and treated with letrozole for 24 h until day 3. At the end
of 24 h incubation with letrozole, the cells were again washed
and incubated in FM for a further 24 h, with cells being assessed
for apoptosis and necrosis on day 4.
Group 3, ‘ZA and letrozole together’: Cells were treated with
ZA and letrozole, both administered together on day 1. After 24 h
(day 2), cells were washed and further incubated in FM until day 4.
Control groups: Cells were treated with negative and positive
controls as follows:
with FM alone (days 1–4);
with ZA (days 1 and 2, added and removed at the same time as
ZA in group 2 or 3, and 1, respectively, and cells further incubated
in FM until day 4);
with letrozole (days 1 and 2, added and removed at the same
time as letrozole in group 1 or 3, and 2, respectively, and cells
further incubated in FM until day 4).
In all groups, cells were assessed for levels of viable, apoptotic
and necrotic cells on day 4, as detailed in the above section.
Statistical analysis
Statistical analysis was performed using SPSS 11 for Mac OS X.
For analysis of differences between means, one-way analysis
of variance or the Kruskal–Wallis test for non-parametric data
was used. Post hoc analysis was carried out using Tukey’s
HSD, Dunnett’s or the Games–Howell test, as appropriate. For
non-parametric data, post hoc analysis was performed using the
Mann–Whitney U-test, with a Bonferroni correction applied.
All experiments were repeated at least three times, and graphs
represent the mean of combined experiments with bars represent-
ing the s.e.m., unless otherwise indicated.
RESULTS
Effect of letrozole on the growth and survival of MCF7-Ca
breast cancer cells
The MCF7-Ca cells were grown and treated with letrozole
(0–100 nM) for up to 72 h in oestrogen-depleted media with
addition of AD. Only after 72 h of treatment was there a significant
growth inhibition with 100 nM (P¼ 0.001 vs control), whereas 24
and 48 h of treatment with letrozole did not significantly inhibit
cell growth (Figure 2). Treatment of cells with letrozole for 72 h,
however, resulted in a significant dose-dependent increase in the
percentage of apoptosis (Po0.0001) (Figure 2). A volume of 10 and
100 nM of letrozole induced 10.7 and 18.1% apoptosis compared
with control levels of 7% (P¼ 0.47 and Po0.001, respectively). It is
interesting that, even with the highest concentration of letrozole,
the levels of necrosis were not significantly greater than those in
control samples, indicating that the mode of induced cell death of
letrozole under these conditions is apoptosis (Figure 3).
Effect of ZA on growth and survival of MCF7-Ca breast
cancer cells
In contrast to the growth-inhibitory effect of letrozole on MCF7-Ca
cells, exposing the cells to ZA (0–25 mM) for only 1 h induced
significant growth inhibition with as little as 1 mM of ZA. This
caused a 35.8% reduction in cell proliferation, compared with that
in control (P¼ 0.0025). A similar growth-inhibitory effect was
obtained with 10mM (37.2% reduction in proliferation, P¼ 0.03)
and 25 mM (5.2% reduction in proliferation, P¼ 0.005) (Figure 4).
To investigate the apoptosis-inducing effects of ZA, initial
experiments investigated the effect of ZA (0–25 mM) treatment of
MCF7-Ca cells for 72 h continuously. This induced a significant
concentration-dependent increase in apoptosis and necrosis, with
a maximal level of 21.4% (Po0.01) and 39.3% (Po0.01),
respectively, with 25 mM (Figure 5A). Concentrations of at least
1 mM of ZA induced a significant increase in apoptosis compared
with control, whereas a concentration of at least 10 mM was
required to induce significant necrosis.
After a standard 4mg infusion of ZA, serum concentrations
rapidly fall within 1–2 h as the drug localises to the bone (Chen
et al, 2002). When MCF7-Ca cells were treated with ZA (0–25 mM)
for 1 h, followed by a 72 h incubation in FM, there was still a
concentration-dependent increase in apoptosis, compared with
control. Apoptosis that was significantly greater compared with
that in untreated controls occurred with at least 1 mM. The maximal
apoptosis induced was 3.6% with 25 mM of ZA (Po0.001, compared
with control). Significantly increased levels of necrosis were only
caused by the highest concentration of ZA (25mM) (4.7 vs 2% in
control, P¼ 0.011) (Figure 5B).
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Figure 2 Growth inhibition of MCF7-Ca cells treated with letrozole
(0–100 nM) for 24–72 h (*P¼ 0.001 vs control).
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Figure 3 Induction of apoptosis vs necrosis in MCF7-Ca cells after
treatment with letrozole (0–100 nM) for 72 h continuously in oestrogen-
free media (*Po0.05 and **Po0.001 vs control).
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Collectively, these results indicate that MCF7-Ca cells are
sensitive to the apoptosis-inducing effects of ZA, even when used
for a short period of 1 h. When extending the incubation period,
there is a significant increase in the levels of apoptosis, but with an
accompanying increase in necrotic cell death.
Effect of sequential ZA and letrozole on induction of
MCF7-Ca breast cancer cell apoptosis
We next investigated the combined effects of ZA and letrozole on
MCF7-Ca cells, and whether drug sequencing had any effect on the
levels of apoptosis. For these experiments, MCF7-Ca cells were
treated with ZA (10mM) and letrozole (100 nM), each for 24 h, alone
and in combination, in oestrogen-free media supplemented with
AD (25 nM), as explained in the ‘Materials and Methods’ section.
As shown in Figure 6, increased levels of apoptosis occurred
when cells were treated with letrozole and ZA. However, this was
sequence dependent. Treating cells with letrozole, followed by ZA,
induced a level of apoptosis that was eight times greater than
treatment with letrozole alone (3.2 vs 0.4%, Po0.001) and nearly
five times greater than that with ZA alone (3.2 vs 0.7%, Po0.001)
(Figure 6A). However, treating cells with ZA, followed by letrozole,
induced only a total of 0.8% apoptosis, which was not significantly
greater than treatment with either drug alone (Figure 6B).
Similarly, treating cells simultaneously with ZA and letrozole
together induced only 0.4% apoptosis, again not significantly
greater than that with either drug alone (Figure 6C).
Finally, the sequence ‘letrozole then ZA’ induced significantly
more apoptosis than either the sequence ‘ZA then letrozole’
(Po0.001) or the sequence ‘ZA plus letrozole’ (Po0.001). In all
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Figure 5 (A) Induction of apoptosis vs necrosis in MCF7-Ca cells after treatment with zoledronic acid (0–25 mM) for 72 h continuously (*Po0.05 and
**Po0.01 vs control). (B) Induction of apoptosis vs necrosis in MCF7-Ca cells after treatment with zoledronic acid (0–25 mM) for 1 h (*Po0.05, **Pp0.01
and yPo0.001, compared with untreated controls).
Letrozole then zoledronic acid
‘Oestrogen-free RPMI+AD’
Zoledronic acid then letrozole
‘Oestrogen-free RPMI+AD’
Together
‘Oestrogen-free RPMI+AD’
% Apoptosis % Apoptosis % Apoptosis
%
 A
po
pt
os
is
5
A B C
4
3
2
1
0
%
 A
po
pt
os
is
5
4
3
2
1
0
%
 A
po
pt
os
is
5
4
3
2
1
0
*
*
Drug treatments
Control Let Zol Let then zol
Drug treatments
Control Let Zol Zol then let
Drug treatments
Control Let Zol Together
Figure 6 The effect of drug sequencing with ‘letrozole followed by ZA’ (A), ‘ZA followed by letrozole’ (B) and ‘ZA and letrozole together’ (C) on
resultant apoptosis when MCF7-Ca cells are treated with letrozole (100 nM) and zoledronic acid (10 mM), each for 24 h in oestrogen-free media plus AD
(*Po0.001, compared with the drugs in combination).
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Figure 4 Growth inhibition of MCF7-Ca cells treated with zoledronic
acid (0–25 mM) for 1 h (*Po0.05 and **Po0.01 compared with untreated
controls).
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three treatment groups (‘letrozole then ZA’, ‘ZA then letrozole’ and
‘ZA and letrozole together’), the levels of necrosis were not
significantly different compared with those in untreated controls.
In summary, these results indicate that when MCF7-Ca cells are
treated with letrozole and ZA in combination, only treating cells
sequentially with letrozole followed by ZA induces substantially
increased levels of apoptosis suggestive of synergy.
Effects of low, clinically relevant concentrations of ZA
As discussed earlier, ZA leaves the circulation rapidly after intra-
venous infusion to localise to the bone, with plasma peak levels
of around 1 mM for 1 h (Chen et al, 2002). Consequently, having
established that there is potential for enhanced levels of apoptosis
when breast cancer cells are treated with letrozole followed by ZA,
it was of interest to determine whether this effect could be achieved
using a concentration of ZA that more accurately reflects peak
circulating levels.
For initial experiments, MCF7-Ca cells were treated with
letrozole (100 nM for 24 h), and thereafter with 10mM of ZA for
1 h only. We found that the resultant levels of apoptosis with
sequential treatment was five times greater than that with ZA alone
(4.0 vs 0.8%, P¼ 0.001), and three times greater than treatment with
letrozole alone (4.0 vs 1.3%, P¼ 0.01) (Figure 7). However, when
the concentration of ZA was further reduced to 1mM, treating
MCF7-Ca cells with letrozole (100 nM for 24 h) followed by 1 mM ZA
for 1 h, the effect of enhanced apoptosis was not observed, with the
resultant apoptosis being 1.3% and necrosis being 1.7%. In neither
case was this significantly greater than treatment with each drug
alone (data not shown). These results suggest a potentially
synergistic relationship. Though not reproducible using a very
low concentration of ZA, synergy is induced with 10mM, a concen-
tration that could be achieved within the bone microenvironment.
Function of the mevalonate pathway on ZA- and
letrozole-induced apoptosis
To assess whether increased levels of apoptosis induced by ZA
and letrozole in combination is, at least in part, due to inhibition
of the mevalonate pathway by ZA, the effect of the addition of
GGOH was investigated. Geranylgeraniol is a distal component
of the mevalonate pathway. If the mechanism of induced apoptosis
is through inhibition of this pathway, we would expect the levels
of apoptosis to be restored when GGOH is added to cells being
treated with ZA and letrozole. Cells (MCF7-Ca) were treated with
letrozole (100 nM, 24 h), and thereafter with ZA (10mM, 1 h, with
or without 50 mM GGOH, added and removed simultaneously
with ZA).
For cells treated with letrozole followed by ZA, the resultant
apoptosis was 4.0%, a level that was significantly greater than
that caused by letrozole alone (1.3%, P¼ 0.011), ZA alone (0.8%,
P¼ 0.001) or GGOH alone (0.3%, Po0.001) (Figure 8). The
addition of GGOH to cells treated with letrozole followed by ZA
reduced levels of apoptosis by 50% (2% with GGOH vs 4% without,
P¼ 0.05).
These results indicate that the increased level of apoptosis
obtained when cells are treated with letrozole followed by ZA is, in
part, through inhibition of the mevalonate pathway, as a
component of this pathway, GGOH, restores levels of apoptosis
by up to 50%.
DISCUSSION
We have evaluated the in vitro effects of different doses of
letrozole and ZA, alone and in combination, on MCF7-Ca cell
proliferation and apoptosis. As a single agent, letrozole alone
significantly inhibited the growth of cells only after 72 h incubation
with the highest tested concentration (100 nM). This suggests
that growth inhibition by letrozole in vitro is not as important as
the effects on apoptosis, as 100 nM of letrozole induced up to 18%
apoptosis.
The ZA effectively inhibited the growth of these cells. Even just
1 h of treatment (followed by a drug-free incubation period)
caused significant growth inhibition, with concentrations as low as
1 mM. However, to detect this inhibitory effect, cells were incubated
in fresh medium for up to 72 h after exposure to the drug. This
period is required for a turnover of (already) prenylated proteins
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Figure 7 The effect of drug sequencing with letrozole followed by ZA
on apoptosis when a clinically relevant concentration of ZA is used
(*Po0.01 for letrozole followed by ZA vs each drug alone).
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Figure 8 The effect of the mevalonate pathway intermediary,
geranylgeraniol (GGOH) (50 mM), on the apoptosis induced by treatment
of MCF7-Ca cells with letrozole (100 nM, 24 h) followed by zoledronic acid
(10 mM, for 1 h) (*P¼ 0.05 compared with ‘letrozole followed by ZA’).
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before inhibition of the mevalonate pathway by ZA (Neville-Webbe
et al, 2005) and subsequent apoptosis.
In combination, ZA and letrozole have potential for synergistic
induction of MCF7-Ca cells in vitro. However, increased induction
of apoptosis only occurred when cells were treated with letrozole
followed by ZA. ‘Letrozole then ZA’ induced a level of apoptosis
that was over eight times greater than that caused by letrozole
alone, and 4.8 times greater than treatment with ZA alone.
The ZA has consistently shown potential for synergistic inter-
action with drugs commonly used in breast cancer. This includes a
combination with paclitaxel (Jagdev et al, 2001; Neville-Webbe
et al, 2006), tamoxifen (Jagdev et al, 2000) and doxorubicin
(Neville-Webbe et al, 2005). In our earlier study with ZA and
chemotherapy drugs, we have similarly found that sequential
administration of drugs is of paramount importance for inducing
maximal (potentially synergistic) levels of apoptosis. For breast
cancer cells treated with ZA in combination with either doxo-
rubicin or paclitaxel, as with letrozole, cells had to be treated with
the chemotherapy drug first, and thereafter with ZA. Treating
cancer cells with the reverse sequence, or even simultaneously,
was either antagonistic or, at best, additive, and the same patterns
were seen here with letrozole. Our group recently evaluated this
sequence-dependent synergy in an in vivo soft-tissue breast
tumour model (Ottewell et al, 2008a, b). Using clinically relevant
doses of doxorubicin and ZA, inhibition of tumour growth was
shown to be sequence dependent with doxorubicin followed by ZA,
leading to inhibition of tumour growth associated with evidence
of enhanced tumour cell apoptosis and reduced proliferation.
The biological effects of letrozole and ZA are largely mediated
through the induction of apoptosis. It is likely that this is enhanced
through inhibition of the mevalonate pathway. Using an inter-
mediary of this pathway (GGOH), apoptosis was reduced by 50%
for cells treated with the sequence ‘ letrozole then ZA’. Inhibition
of the mevalonate pathway by nitrogen-bisphosphonates is integral
for inducing a variety of effects including apoptosis of osteoclasts
(Amin et al, 1992), breast cancer cells (Jagdev et al, 2001), prostate
cancer cells (Oades et al, 2003), myeloma cells (Shipman et al,
1998) and inhibition of tumour cell invasion (Denoyelle et al,
2003). Furthermore, inhibition of this pathway also contributes to
the apoptosis induced when breast (and prostate) cancer cells are
treated in combination with ZA and doxorubicin (Neville-Webbe
et al, 2005), or when breast cancer cells are treated with ZA and
paclitaxel (Neville-Webbe et al, 2006).
Although in vitro and in vivo studies have limited implications
for the clinical setting, it is interesting to note a recent update of
the ZO-FAST study (Eidtmann et al, 2008). This clinical trial
assesses the effects of ZA on letrozole-induced bone loss in post-
menopausal women with early breast cancer. Patients are
randomised to either combined letrozole and ZA (4mg every
6 months) or letrozole alone. A recent update, with a 36-month
follow-up, suggested a better outcome for those treated with the
combination, with a 41% risk reduction in cancer recurrence.
Although these results are preliminary, and the trial was not speci-
fically set up to address the anti-tumour potential of ZA in patients
receiving letrozole, they add to the growing evidence of the direct
anti-cancer effects of this bisphosphonate in combination with
other drugs, including endocrine treatments. Similarly, in the
ABCSG 12 trial of pre-menopausal breast cancer patients (Gnant
et al, 2009), 1803 patients received ovarian suppression with
goserelin and were then randomised to receive either tamoxifen or
the AI anastrazole, with or without ZA (4mg infusions every
6 months for 3 years). No significant differences in disease-free
survival were seen between tamoxifen and AI. However, the group
receiving ZA had a statistically significant 36% reduction in the risk
of disease recurrence, compared with patients receiving endocrine
therapy alone (P¼ 0.01). The reduction in metastatic events was not
confined to a reduction in the frequency of bone metastases alone,
but also applied to distant metastatic sites, loco-regional recurrence
rates and cancer of contralateral breast. Reduction of metastases
outside the skeleton adds to the growing evidence that the anti-
tumour effects of ZA are not confined to the bone, and such anti-
tumour effects may be enhanced by combination with other drugs.
In summary, letrozole has anti-tumour activity (which is largely
through induction of apoptosis) when used alone under culture-
media conditions that mimic the post-menopausal state. When
combined with ZA, there is potential for a synergistic induction of
apoptosis, but only when cancer cells are treated with letrozole
followed by ZA. This may have positive implications for post-
menopausal patients receiving both these drugs in the clinical
setting.
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